Harvey D. White
New Zealand cardiologist
Cardiac tamponade in the fibrinolytic era: analysis of >100,000 patients with ST-segment elevation myocardial infarction.Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level dataEffects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroupsIncidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy.International variation in the use of blood transfusion in patients with non-ST-segment elevation acute coronary syndromes.International variation in the use of evidence-based medicines for acute coronary syndromesLessons learned from a clinical trialMeta-analysis of intracranial hemorrhage in acute coronary syndromes: incidence, predictors, and clinical outcomesMeta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventionsNoninvasive, medical management for non-ST-elevation acute coronary syndromesOutcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomesOutcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials.Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trialsSignificance of atrial fibrillation during acute myocardial infarction, and its current management: insights from the GUSTO-3 trialStatin use and sex-specific stroke outcomes in patients with vascular diseaseSustained ventricular arrhythmias among patients with acute coronary syndromes with no ST-segment elevation: incidence, predictors, and outcomes.The evolving role of direct thrombin inhibitors in acute coronary syndromesThe failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac eventsThe impact of anthropomorphic indices on clinical outcomes in patients with acute ST-elevation myocardial infarctionTrends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment-Elevation Acute Coronary Syndromes Clinical TrialsUpstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials
author
Harvey D. White
New Zealand cardiologist
alternateName
Harvey Douglas White
@en
Harvey White
@en
award
birthDate
2000-01-01T00:00:00Z
gender
mainEntityOfPage
sameAs
/g/122h5syf
type
comment
New Zealand cardiologist
@en
cardioloog uit Nieuw-Zeeland
@nl
cardiólogu neozelandés
@ast
neuseeländischer Mediziner
@de
label
Harvey D. White
@ast
Harvey D. White
@de
Harvey D. White
@en
Harvey D. White
@es
Harvey D. White
@fr
Harvey D. White
@nl
Harvey D. White
@sl
Harvey D. White
@sq
Уайт, Харви (кардиолог)
@ru
হার্ভে ডি হোয়াইট
@bn